Treatment strategies for recurrent hepatitis C after living donor liver transplantation (from Kyushu University experience)
|
|
- Jordan Lambert
- 5 years ago
- Views:
Transcription
1 Korean Association of HBP Surgery President: Dong Wook Choi, MD, PhD, Samsung Medical Center Session : 09:50-10:50, 2 nd /3, Apr 27, 2013 Venue: Lotte Hotel, Jeju Island, Korea Session: Prevention of original disease recurrence after liver transplantation Treatment strategies for recurrent hepatitis C after living donor liver transplantation (from Kyushu University experience) Department of Surgery and Science, Kyushu University Toru Ikegami, MD
2 Today s topics 1. What determines IFN sensitivity for Hepatitis C after LT? (Viral factors vs. Host factors) 2. Telaprevir based new antiviral treatment for Hepatitis C after LT (Telaprevir will be available in Korea in 2015) 3. Diagnosis and treatment for cholestatic Hepatitis C after LT
3 Today s topics 1. What determines IFN sensitivity for Hepatitis C after LT? (Viral factors vs. Host factors) 2. Telaprevir based new antiviral treatment for Hepatitis C after LT (Telaprevir will be available in Korea in 2015) 3. Diagnosis and treatment for cholestatic Hepatitis C after LT
4 Case numbers The cases of living donor liver transplantation, Kyushu University Total 454 cases HCV (-) n=294 (64.8%) HCV (+) n=160 (35.2%) (year)
5 The most significant problem: recurrent hepatitis C after LDLT F1 recurrence F3-4 recurrence (%) % 78.7% 97.8% % Post-transplant years Post-transplant years 7
6 Significance of IFN treatment for recurrent Hep C 1 year after LT 3 years after LT F1 F4 x40 2 years after LT 68y.o. female, LDLT for Hep C and HCC F2 x40 7 years after LT IFN treatment (SVR) F1 x40 x40 IFN treated fibrosis
7 Overall outcomes after IFN treatment for hepatitis C, Kyushu University Conventional IFN (n=6) Peg-IFN with ribavirin (n=111) NR (no response) (n=4,66.7%) NR (n= %) VR (viral response) (n= %) EVR (n=17, 24.6%) No-EVR (n=52, 75.4%) SVR (n=2 33.3%) Relapse (n=10 9.0%) (SVR:47.9%) SVR (n= %) On treatment (n=5 4.5%) SVR: sustained viral response (no HCVRNA over 6 months after finishing IFN treatment)
8 SVR rate (%) SVR rate (%) SVR rate (%) SVR rate (%) Which factors are associated with IFN sensitivity? Vital genotype Elderly recipient ( 60) p=0.231 p= % 64.7% 51.2% 46.2% Type 1 (n=90) Type 2 (n=17) No (n=86) Yes (n=26) HCVRNA ( 5LogIU/ml) p=0.985 Donor age 40 p= % 50.5% 51.2% 46.7% No (n=4) Yes (n=107) No (n=30) Red characters: generally believed favorable factors Yes (n=82)
9 Does mutation in HCV genomic RNA impacts IFN sensitivity? Structural (viral structures) Non Structural (RNA replication) Favorable: wild Favorable: mutant Wild type amino acid 70 and 91 in the core portion, mutated ISDR and IRRDR in NS-5A have been identified for significant factors for increased IFN sensitivity in non-transplant cases.
10 SVR rate (%) Role of HCV mutations in IFN sensitivity after LDLT Known favorable factors: double wile core protein, mutant ISDR and IRRDR Double wild AA 70/91 (core protein) 39.7% p=0.055 (n.s.) 61.3% SVR rate (%) SVR rate (%) Mutated ISDR ( 2) p=0.080 (n.s.) 59.4% 40.0% No (n=55) Yes (n=32) Mutated IRRDR ( 6) p=0.067 (n.s.) 60.7% 39.7% No (n=53) Yes (n=31) No (n=58) Yes (n=27)
11 Genome-wide analysis for IFN sensitivity (host) Smaller p-value (Nat Genet 41: , 2009) (Nat Genet 41: , 2009) 19q3 IL28B (IFNλ3) rs AAAC[G/A]GAC G rs CAAT[G/T]TCAT Numerous SNPs on chromosomes Chromosome 19 IL28A (IFNλ2) Genome-wide analysis showed that single nuclear polymorphisms close to the IL28B (IFN λ3) gene were significantly associated with the sensitivity of IFN treatment for chronic hepatitis C. rs : TT = high IFN sensitivity, TG or GG = low IFN sensitivity
12 Dual grafts LDLT from two donors with different IL28B genotypes Minor Major Donor for Rt lobe graft 42 y.o Female Recipient s spouse rs : T / G Donor for Lt lobe graft 21 y.o Male Recipient s son rs : T / T Minor Recipient 51y.o Male, Hep-C HCC rs : T / G Peg-IFN and Ribavirin
13 Intrahepatic HCV-RNA and IL28B genotype (4 years after LDLT) Rt lobe graft Lt lobe graft Donor rs T/G (Minor) Donor rs T/T (Major) A2F2 A1F0 HCV RNA quantitative RT-PCR 15.3 copies / µg undetectable Motomura T et al. Am J Transpl. 2011
14 Paraffin embedded specimen could be used for IL28B genotyping Sliced paraffin embedded specimen Hybridized and polymerized for luminescence DNA isolator PS TM Applied Biosystems StepOne TM Isolated DNA G/G rs T/G rs T/T rs
15 Donor and Recipient IL28B genotype determines IFN sensitivity (SVR) Factors No (SVR rate) Yes (SVR rate) p-value Recipient age >60 years 38/68 (55.8) 18/44 (40.9) Recipient gender, male 23/47 (48.9) 33/65 (50.8) Donor age <40 years 14/30 (46.7) 42/82 (51.2) Left lobe graft 18/42 (42.8) 38/70 (54.3) Splenectomy 17/43 (39.5) 39/69 ( Early IFN induction within 3 mo 42/82 (51.2) 13/28 (46.4) Biliary stenosis 40/78 (51.3) 16/34 (47.1) Acute rejection 51/101 (50.5) 5/11 (45.5) FK use 26/45 (57.8) 30/67 (44.8) Steroid use 9/21 (42.8) 47/91 (51.6) Type 1 HCV 11/17 (64.7) 44/90 (48.9) HCV-RNA 5 logiu/ml 2/4 (50.0) 54/107 (50.5) R-IL28B-TT genotype (Major) 4/31 (12.9) 50/77 (64.9) <0.001 D-IL28B-TT genotype (Major) 5/27 (18.5) 47/74 (63.5) <0.001 Core AA (70/91:DW) 21/53 (39.7) 19/31 (61.3) ISDR mutation 2 22/55 (40.0) 19/32 (59.4) IRRDR mutation 6 23/58 (39.7) 17/28 (60.7) IL-28B-genotypes determines SVR
16 Both donor and recipient IL28B determines IFN sensitivity after LDLT Genome-wide analysis Chromosome #19 IL28B (rs ) rs (%) SVR rate p< % rs genotype Major (M):TT Minor (m):tg GG % 14.3% 12.5% Donor IL28B m m M M Recipient IL28B m M m M N (%) 18 (16.7%) 7 (14.3%) 8 (12.5%) 65 (66.3%) Major: TT minor: TG or GG
17 Today s topics 1. What determines IFN sensitivity for Hepatitis C after LT? (Viral factors vs. Host factors) 2. Telaprevir based new antiviral treatment for Hepatitis C after LT (Telaprevir will be available in Korea in 2015) 3. Diagnosis and treatment for cholestatic Hepatitis C after LT
18 Telaprevir for hepatitis C after liver transplantation Telaprevir (will be available in Korea in 2015, has been available in Japan last year) : NS3-4A serine protease inhibitor, inhibits the release of proteins involved for RNA replication Structural (viral structures) Non Structural (RNA replication) NS3-4A protease release all the proteins involved for RNA replication Telaprevir inhibits master switch (NS3-4A) for RNA replication of HCV
19 Telaprevir and CNI (Cyclosporine, Taclorimus) Increase of Cyclosporine level X 4.6 Increase of Taclorimus level X 70 Garg, et al. Hepatology 2011
20 German team used full-dose Telaprevir for LT patients Case 58M 67M 71M 51M 70F 59F 53M 58M 61M Cr IS Tac Tac Tac Tac Sir CyA CyA CyA CyA IL28B (CC:major) Pre-Tx CT CT CT CT CT TT CT CT CT Peg- IFN RBV FK: 1/22 dosage, CyA: 1/2.5 dosage - Peg-IFN Peg-IFN RBV Peg-IFN RBV Peg-IFN RBV Peg-IFN RBV Peg-IFN RBV Peg-IFN RBV NR - NR NR TR NR NR NR NR Peg-IFN 2b 2a 2a 2a 2a 2a 2a 2a 2a RBV G-CSF Yes Yes - EPO Yes Yes Yes Yes Yes Yes RCC Yes Yes Yes Yes Yes Yes Effect RVR RVR RVR NR EVR EVR EVR RVR EVR EVR; 88.9% RBC was given for 6/9 (66.7%) Wemer, et al. Liver Transpl 2012
21 Reduced telaprevir for recurrent Hep-C after LDLT at Kyushu Univ. Indication:NR or TR by conventional Peg-IFN and Ribavirin treatment Exclusion:Cr>1.5 mg/dl, Hb<10g/dl Methods Peg-IFN α2b: μg/kg/week Ribavirin:start with 25-50% of regular dosage( mg/day) Telaprevir:1500mg for 12 weeks (reduced from 2250 mg) Cyclosporine:start with 25% dosage(trough は :80-150ng/ml) Mycophenolate:continue Dose modification anemia:hb<8.5g/dl(2-6w) Ribavirin dose reduction rash:grade-ii(diffuse, 1-2w) stop Telaprevir renal:cr>2.0mg/d(1-2w) stop Telaprevir Skin problem Anemia, renal problem Increase Cyclosporine dosage Telaprevir Peg-IFN+RIbavirin 4w 12w 24w
22 Triple therapy including Telaprevir for rec. Hep-C after LDLT Case 52, M 63, M 70, M 59, M 64, F 56, M Previous IFN Yes Yes Yes Yes Yes Yes Outcome after prev.ifn TR NR NR NR TR NR HCV-genotype 1b 1b 1b 1b 1b 1b HCV-RNA (logiu/ml) IL28B (Recipient) TT TG TT TT TG TT IL28B (Donor) TT TG TT TT TG TT AA70(R) R Q R R Q Q AA91(L) L L L L M M CNI CyA CyA CyA CyA CyA CyA MMF Peg-IFN TPV RBV G-CSF No No No No No No EPO No No No No No No RBC Yes No No No No No Rash Grade 1 No No No No Grade 1 Inquantitiable HCVRNA Undetectable HCVRNA NA 4 11 Effect EVR EVR RVR NR RVR EVR EVR: 83%
23 HCV-RNA (log IU/ml) Triple therapy including Telaprevir for rec. Hep-C after LDLT (Changes in HCV-RNA titer) RVR 33.3% EVR 83.3% Undetectable 33.3% 83.3% (weeks) HCV-RNA (2/6) (5/6)
24 Hemoglobin (g/dl) Triple therapy including Telaprevir for rec. Hep-C after LDLT (Changes in Hemoglobin) Decrease in hemoglobin: 4.4 ± 0.9 g/dl (weeks)
25 Creatinine (mg/dl) Triple therapy including Telaprevir for rec. Hep-C after LDLT (Changes in creatinine) Increase in serum creatinine 0.4 ± 0.1 mg/dl (weeks)
26 Cyclosporine concentration (ng/dl) Triple therapy including Telaprevir for rec. Hep-C after LDLT (Changes in cyclosporine trough level) ± 22 ng/dl (weeks)
27 Today s topics 1. What determines IFN sensitivity for Hepatitis C after LT? (Viral factors vs. Host factors) 2. Telaprevir based new antiviral treatment for Hepatitis C after LT (Telaprevir will be available in Korea in 2015) 3. Diagnosis and treatment for cholestatic Hepatitis C after LT
28 T.Bil (mg/dl) HCVRNA (KIU/ml) ALT (IU/L) Cholestatic hepatitis after LDLT: Very serious condition! A1 cholestatic 18 9 万 Day 9 Day 万 万 Dead at Day Saraf N. Liver Transpl
29 Cholestatic hepatitis C after liver transplantation 1. Later than 1 month after transplantation (usually <6 months) 2. Serum bilirubin level greater than 6 mg/dl 3. Serum ALP and GGT greater than 5x the upper limits of normal value 4. Ballooning of hepatocytes, paucity of inflammation, and variable degrees of cholangiolar proliferation 5. High serum HCV RNA levels 6. Absence of surgical biliary complications Mortality: over 50%? Difficult to diagnose (acute rejection, preservation injury, functional choestasis) Narang T, et al. 2010
30 Histologic findings of cholestatic hepatitis after LDLT Pt #2 Pt #4 x40 Minimal lymphocyte aggregation x40 Minimal lymphocyte aggregation Pt #3 Pt #6 x40 Minimal lymphocyte aggregation x40 Minimal lymphocyte aggregation No cholestasis, hepatocyte ballooning, high HCVRNA titer, hyperbilirubinemia
31 Which factors are associated with cholestatic hepatitis after LDLT? Factors Cholestatic hepatitis No (n=44) Yes (n=5) p-value Recipient age 57.4 ± ± Donor age 34.5 ± ± Graft standard liver volume ratio (%) 39.2 ± ± Splenectomy 42 (95.5) 5 (100.0) Recipient IL28B genotype, T/T 23 (60.5) 4 (80.0) Donor IL28B genotype, T/T 27 (64.3) 4 (80.0) HCV genotype 1, yes 34 (80.9) 3 (60.0) HCV-RNA titer (log 10 IU/ml) Before LDLT 5.4 ± ± weeks after LDLT 5.8 ± ± Peak value 6.8 ± ± VR (%) 22 (64.7) 5 (100.0) Taclorimus use 22 (50.0) 1 (20.0) Acute rejection 1 (2.3) 0 (0.0) Biliary stenosis 8 (18.2) 2 (40.0) CMV infection 12 (27.2) 4 (80.0) 0.017
32 HCV-RNA titer and cholestatic hepatitis Appropriate cut off for cholestatic hepatitis C ROC curve HCV-RNA=8.0 log/ml 2 weeks after LDLT Pt #5 Lobular hepatitis and hepatocyte ballooning
33 IFN treatment for cholestatic hepatitis after LDLT Recipient Donor genotype HCV RNA (log) Onset (months) T.Bil (mg/dl) Recipient IL2bB-SNP Donor IL28B-SNP IFN effect Follow-up (year)) 40, M 39, M 1b Minor Minor IFNα NR M 28 M 1b Major Major Peg-α2b SVR F 21 F 1b Major Major Peg-α2b VR F 36 M 2a Minor Minor Peg-α2a SVR M 20 M 1b Major Major Peg-α2b SVR F 27 M 2a Major Major Peg-α2b VR F 43 F 1b Major Major Peg-α2a SVR % major combination VR: 85.7% The key is early recognition, diagnosis and initiation of treatment
34 Summary Combination of donor and recipient IL28B is a significant predictor for IFN sensitivity for recurrent hepatitis C after LDLT. Telaprevir based antiviral treatment is a feasible option for recurrent hepatitis C for selected patients after LDLT. Cholestatic recurrent hepatitis C after LDLT could be successfully treated by early pathological and virological diagnosis and early IFN installation.
Efficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience
Efficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience A. Coilly, B. Roche, J. Dumortier, D. Botta-Fridlund, V. Leroy,
More informationDetection and significance of PD-1.3 SNP (rs ) and IL28B SNP (rs ) in patients with current or past hepatitis B virus (HBV) infection
Detection and significance of PD-1.3 SNP (rs11568821) and IL28B SNP (rs12979860) in patients with current or past hepatitis B virus (HBV) infection Asterios Saitis 1, Nikolaos K. Gatselis 1, Kalliopi Azariadi
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationOptimal ltherapy in non 1 genotypes:
Optimal ltherapy in non 1 genotypes: genotype 2 and 3 patients Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy craxanto@unipa.it Peg IFN alpha plus ribavirin : SVR rate of >80%
More informationHepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Hepatitis C: New Antivirals in the Liver Transplant Setting Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Patient survival Hepatitis C and Liver Transplantation Years after transplantation
More informationTransplantation. Professor Didier. Centre Hépatobiliaire, Hépatobiliaire, C.H.B.
Treatment Treatment of of Hepatitis Hepatitis C C in in Liver Liver Transplantation Transplantation Professor Professor Didier Didier Samuel Samuel Centre Centre Hépatobiliaire, Hépatobiliaire, Inserm
More informationEPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE
EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE E. Angeli, A. Mainini, C. Atzori, G. Gubertini and G. Rizzardini II Dept. Infectious
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationCASE STUDY. Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be?
Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be? CASE STUDY Pham Thi Thu Thuy MD, PhD Ho Chi Minh City Vietnam Serious Adverse
More informationHCV TREATMENT PRE- AND POST TRANSPLANTATION
HCV TREATMENT PRE- AND POST TRANSPLANTATION Mitchell L. Shiffman, MD, FACG Medical Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA IVer Liver Institute
More informationUNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS PHARMACOGENETICS AND THE APPLICATION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN
More informationTreatment of chronic hepatitis C in HIV co-infected patients
Treatment of chronic hepatitis C in HIV co-infected patients Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain The most prevalent chronic viral infections in humans HBV
More informationReduced telaprevir dosing in combination therapy for patients with chronic hepatitis C
Original Contribution Kitasato Med J 2017; 47: 1-9 Reduced telaprevir dosing in combination therapy for patients with chronic hepatitis C Wataru Ando, 1 Yumi Fukunaga, 1 Hiroaki Yokomori, 2 Takako Komiyama
More informationLiver transplantation and hepatitis C virus
Liver transplantation and hepatitis C virus Where do we come from? Where are we? Where are we going? François Durand Hépatologie & Réanimation Hépato-Digestive INSERM U1149 Hôpital Beaujon, Clichy HCV:
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationMEDIC CENTER. Case 2
Case 2 Case history 57 year old Vietnamese man He lives in HCM city and works as a engineer The patient presented in July 2012 with fatigue Diagnosed with HCV in 2004 Negative for both HBV and HIV antibodies
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationHEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation
HEPATITIS WEB STUDY Treatment of Hepatitis C following Liver Transplantation Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah Health Sciences
More informationIL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?
IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? Francesco Paolo Russo Department of Surgery, Oncology and Gastroenterology Multivisceral/ Gastroenterology Section University
More informationTreatment of recurent hepatitis infection after liver transplantation
Paris PHC, 11 janvier 2016 Treatment of recurent hepatitis infection after liver transplantation Georges-Philippe Pageaux CHU Saint Eloi, Digestive department gp-pageaux@chu-montpellier.fr Disclosures
More informationTreatment of Hepatitis C Recurrence after Liver Transplantation. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Treatment of Hepatitis C Recurrence after Liver Transplantation Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Agenda 1. Introduction 2. Treatment options for hepatitis C recurrence after transplantation
More informationHepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationDAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France
DAA-based treatment in cirrhotic and post-transplanted patients Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France Cirrhosis and transplantation 2 populations with similar issues Hepatic impairment
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationPersonalizzazione della Cura in Epatologia. Epatite Cronica C: Pazienti con Genotipo 2
Monotematica AISF 213 Personalizzazione della Cura in Epatologia Pisa, 17-19 Ottobre 213 Epatite Cronica C: Pazienti con Genotipo 2 Maria Grazia Rumi U.O. Epatologia, Ospedale San Giuseppe Università degli
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationLaboratory and Clinical Diagnosis of HCV Infection
Laboratory and Clinical Diagnosis of HCV Infection Jean-Michel Pawlotsky,, MD, PhD Department of Virology (EA 3489) Henri Mondor Hospital University of Paris XII Créteil,, France I Nonspecific Liver Tests
More informationROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV
ROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV (Especially HCV-6) WK Seto Clinical Assistant Professor Department of Medicine Queen Mary Hospital The University of Hong Kong HCV GENOTYPES:
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING?
ASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING? DO WE NEED LIVER BIOPSY? Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA POTENTIAL
More informationHepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011
Hepatitis C Update Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011 Outline n Educational Objectives Epidemiology and Natural History of Hepatitis C Current Treatment
More informationCurrent Treatments for HCV
Current Treatments for HCV Mitchell L. Shiffman, MD, FACG Advisory Committee/Board Member: Achillion, Anadys, Boehringer-Ingelheim, BMS, Conatus, Genentech, Gen-Probe, Gilead, Globeimmune, GSK, Janssen,
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationLiver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
More information-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual
2013: HCV Genome -HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual proteins are released from polyprotein
More informationGenotype 4. Sanaa Kamal, M.D., Ph.D. Professor. Ain Shams University, Cairo, Egypt Tufts School of Medicine
Optimal Therapy in Hepatitis C Genotype 4 Sanaa Kamal, M.D., Ph.D. Professor Ain Shams University, Cairo, Egypt Tufts School of Medicine Boston; USA HCV Genotype 4 True or False HCV-G4 is limited to Africa
More informationBackground. ΝΑ therapy in CHBe- until HBsAg clearance. (EASL guidelines 2012)
Interferon-induced protein 10 (IP10) at discontinuation of effective entecavir (ETV) or tenofovir (TDF) therapy cannot predict subsequent relapses in non-cirrhotic HBeAgnegative chronic hepatitis B (CHBe-)
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationBruce A. Luxon, MD, Ph.D. Anton and Margaret Fuisz Chair in Medicine Professor and Chair Department of Medicine Georgetown University
Bruce A. Luxon, MD, PhD, FACG Bruce A. Luxon, MD, Ph.D. Anton and Margaret Fuisz Chair in Medicine Professor and Chair Department of Medicine Georgetown University Dr. Luxon is on the speakers p bureau
More informationMANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT. Professor Salimur Rahman
MANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT Professor Salimur Rahman Department of Hepatology, BSMMU President, Association for the study of the liver, Dhaka,
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationPrise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques
Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques Future Complications of Darius Moradpour Service de Gastro-entérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationAbstract. Background. Conclusions. Aim. Patients and Methods. Acknowledgments. References. Results. Poster #905
Poster #95 Baseline, Donor, and On-treatment Predictors of Sustained Virologic Response in Treated for Recurrent Hepatitis C Following Orthotopic Liver Transplant: Subanalysis of the PROTECT Study F. D.
More informationTREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING. Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona
TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona Hepatitis C after LT Survival (%) HCV negative HCV positive Time from LT (years) HCV treatment
More informationHepatitis C Medications Prior Authorization Criteria
Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More informationThe Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University
The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and
More informationSOLAR-1 (Cohorts A and B)
Phase 2 Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Charlton M, al. Gastroenterology. 2015; 149:649-59. Ledipasvir-Sofosbuvir
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More informationApproved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationTrapianto di fegato e organi solidi. Pierluigi Toniutto Sezione di Epatologia e Trapianto Epatico Università di Udine
Trapianto di fegato e organi solidi Pierluigi Toniutto Sezione di Epatologia e Trapianto Epatico Università di Udine Case 2 53-yr old white man PSC (CTP score 10, MELD 23, status UNOS 2B) HBsAb-, HBcAb-
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationCase Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation
108 Diagnostic Problems in Hepatology Case Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation Brian Kim, MD 1 Anshu Trivedi, MD
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationEvaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
More informationTriple therapy with telaprevir or boceprevir: management of side effects
Triple therapy with telaprevir or boceprevir: management of side effects Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationTreating HCV After Liver Transplantation: What are the Treatment Options?
4 th OPTIMIZE WORKSHOP USING DAAs IN PATIENTS WITH CIRRHOSIS AND LIVER RECIPIENTS Treating HCV After Liver Transplantation: What are the Treatment Options? Maria Carlota Londoño, MD Liver Unit, Hospital
More informationEmerging Approaches for the Treatment of Hepatitis C Virus
Emerging Approaches for the Treatment of Hepatitis C Virus Gap Analysis 1 Physicians may not be sufficiently familiar with the latest guidelines for chronic HCV treatment, including the initiation and
More informationTreatment of chronic hepatitis B 2013 update
22 February 213 Treatment of chronic hepatitis B 213 update Pietro Lampertico 1st Gastroenterology Unit Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico Università di Milano EASL 212 Clinical
More informationHepatitis C virus (HCV) infection affects 170 million
GASTROENTEROLOGY 2010;139:1577 1585 Variants in IL28B in Liver Recipients and Donors Correlate With Response to Peg-Interferon and Ribavirin Therapy for Recurrent Hepatitis C TAKASUKE FUKUHARA,*, AKINOBU
More informationHPI (2006) Question: Douglas T. Dieterich, MD. What is the risk of mother-to-child transmission in HCV for this woman?
Case Presentation Douglas T. Dieterich, MD Professor of Medicine Mount Sinai School of Medicine HPI (2006) Slide #2 HPI: 30 yo white woman, G0P0. HCV+. PMH & FH: H/o multiple HCV treatments in the past.
More informationBackground: Narlaprevir (SCH )
Once Daily Narlaprevir (SCH 9518) in Combination with Peginterferon alfa-2b/ Ribavirin for Treatment-Naive Patients with Genotype-1 Chronic Hepatitis C: Interim Results from the NEXT-1 Study Vierling J,
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationPatients with Cirrhosis: Managing the HCV Peri-Transplant Patient
Patients with Cirrhosis: Managing the HCV Peri-Transplant Patient Fred Poordad, MD Professor of Medicine University of Texas Health Science Center VP, Academic and Clinical Affairs The Texas Liver Institute
More informationDAAs in the era of decompensated liver disease. Piero L. Almasio University of Palermo
DAAs in the era of decompensated liver disease Piero L. Almasio University of Palermo piero.almasio@unipa.it HCV therapy in the era of interferon based therapy Priority Compensated cirrhosis Decompensated
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationRECENTLY, THE MANAGEMENT of chronic hepatitis
bs_bs_banner Hepatology Research 214; 44 (Suppl. 1): 59 7 doi: 1.1111/hepr.12272 Special Report JSH Guidelines for the Management of Hepatitis C Virus Infection: A 214 Update for Genotype 1 Drafting Committee
More informationHEPATITIS C TREATMENT GUIDANCE
HEPATITIS C TREATMENT GUIDANCE These guidelines have been produced based on the NICE Guidance TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis c and the summaries of product
More informationGenetic Determinants in HCV
Genetic Determinants in HCV Lynn E. Taylor, MD Assistant Professor of Medicine Warren Alpert Medical School of Brown University The Miriam Hospital Providence, RI April 27, 2011 Disclosure My presentation
More informationPredictors of Response to Hepatitis C Therapy in the DAA Era. Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid
Predictors of Response to Hepatitis C Therapy in the DAA Era Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid Why Predicting HCV Response? Select candidates for therapy Prioritizing
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationV.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain, R. Bailey, A. Neumann, P. Cronin, J. McHutchison, E. Pulkstenis, M.
COMPARABLE ANTIVIRAL RESPONSE RATES WITH ALBINTERFERON ALFA-2B DOSED AT Q2W OR Q4W INTERVALS IN NAIVE SUBJECTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C V.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain,
More informationHEPATITIS C UPDATES. Sanaa S. Said 10 th April, 2014
HEPATITIS C UPDATES Sanaa S. Said 10 th April, 2014 CONTENTS Introduction Epidemiology Transmission and Natural history Kenyan guidelines What is new? References INTRODUCTION Hepacivirus genus, Flaviviridae
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationSOLAR-1 (Cohorts A and B)
Phase 2 Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Charlton M, al. Gastroenterology. 2015; [Epub ahead of print]
More informationClinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov
Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients
More informationHCV Management in Decompensated Cirrhosis: Current Therapies
Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu
More information27-28 September 2017, Ljubljana, Slovenia. 3rd CEE Meeting on Viral Hepatitis and Co-infection with HIV
Direct-acting antivirals Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir with or without Ribavirin in HCV genotype 1-infected treatment-naïve or treatment-experienced patients with or without cirrhosis:
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationHépatite E & transplantation d organes Pr Nassim KAMAR
Hépatite E & transplantation d organes Pr Nassim KAMAR Service de Néphrologie, Dialyse et Transplantation d Organes CHU Rangueil- Toulouse Genotype 3 HEV infection is an emerging disease in developing
More informationVicente Soriano Department of Infectious Diseases
Predictors of Response to Hepatitis C Therapy Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain Diagnosis Therapy IL28B alleles Non-invasive liver fibrosis methods Viral
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More information